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Abstract 
Background: Aikeqing (AKQ) has been shown in clinical studies to improve quality of life of HIV/AIDS patients, but 
anti‑HIV activity has not been determined. The SHIV‑infected macaque is an important animal model for testing anti‑
viral drugs. This study aimed to determine the anti‑HIV activity of AKQ in chronically SHIV89.6‑infected Chinese rhesus 
macaques.
Methods: Nine Chinese rhesus macaques were inoculated intravenously with SHIV89.6 virus. At 11 weeks post‑infec‑
tion, the animals were arbitrarily divided into three groups: high‑dose (AKQ 1.65 g/kg; n = 3), low‑dose (AKQ 0.55  
g/kg; n = 3), and control (water 1 mL/kg; n = 3). Treatment was administered by the intragastric gavage route once‑
daily for 8 weeks. Blood (5 mL) was collected biweekly. Viral loads were analyzed by real‑time quantitative RT‑PCR 
assays, and T cell counts were monitored by FACS analyses throughout the treatment.
Results: AKQ induced a persistent decline (P = 0.02) in plasma viral loads during treatment in the high‑dose group 
compared with their baseline levels, and cessation of the therapy caused viral load rebound to the pretreatment 
levels. No significant difference (P = 0.06) was found in the plasma viral loads during treatment in the low‑dose group. 
The CD4+ T cell counts and CD4/CD8 ratios remained at stable high levels during the treatment period.
Conclusion: AKQ reduced plasma viral loads in the SHIV89.6‑infected Chinese rhesus macaque model.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Highly active antiretroviral therapy (HAART) has sig-
nificantly improved the morbidity and mortality of 
HIV-infected patients. A total of 37 licensed drugs are 
available for optimal antiretroviral combinations [1]. 
However, not all patients can profit from long-term 
therapy, and patients may still have an increased risk of 
death from non-AIDS-associated malignancies. Most 
patients receiving HAART have some persistent immune 
dysfunction [2]. Non-AIDS-associated malignancies are 
becoming a large burden on the healthcare system owing 
to the improved survival of HIV-infected patients receiv-
ing HAART.
Increasing evidence has demonstrated that drugs tar-
geting multiple targets of HIV-1 infection usually have 
amplified therapeutic efficacy [3]. Aikeqing (AKQ), 
composed of Radix Aconiti Lateralis Preparata (Fu 
Zi), Herba Epimedii (Yin Yang Huo), Rhizoma Zingib-
eris (Gan Jiang), Radix Glycyrrhizae (Gan Cao), Radix 
Ginseng (Ren Shen), Radix Salviae Miltiorrhizae (Dan 
Shen), Rhizoma Polygoni Cuspidati (Hu Zhang), Poria 
(Fu Ling), Cortex Phellodendri (Huang Bai), and Radix 
Scutellariae (Huang Qin), was designed based on the 
symptoms and characteristics of HIV/AIDS patients 
by investigators at the Institute of Tropical Medicine, 
Guangzhou University of Chinese Medicine [4]. Pilot 
clinical studies [4, 5] reported beneficial effects of AKQ 
in the treatment of HIV patients in China, by improv-
ing their quality of life and reducing side effects related 
to medications. However, the HIV loads and CD4+ T cell 
counts, which are routinely measured to monitor HIV 
disease progression, were not determined in the treated 
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patients because of the associated costs and technical 
constraints.
Rhesus macaques closely resemble humans in anatomy, 
physiology, drug metabolism, and other characteristics. 
Moreover, their susceptibility to SIV/SHIV infection 
makes them a superior animal model for testing of anti-
HIV drugs. Chinese-origin rhesus macaques (Ch-RMs) 
are the most appropriate species for studying SIV/SHIV 
infection and AIDS pathogenesis [6, 7]. To our knowl-
edge, there are no reports on the use of SHIV-infected 
Ch-RMs to test the efficacy of a Chinese medicine.
This study aimed to determine the anti-HIV activity of 
AKQ in chronically SHIV89.6-infected Ch-RMs.
Methods
Herbal materials and AKQ extraction
AKQ was provided by the Tropical Medicine Institute, 
Guangzhou University of Chinese Medicine, and com-
posed of Radix Aconiti Lateralis Preparata, Herba Epi-
medii, Rhizoma Zingiberis, Radix Glycyrrhizae, Radix 
Ginseng, Radix Salviae Miltiorrhizae, Rhizoma Polygoni 
Cuspidati, Poria, Cortex Phellodendri, and Radix Scutel-
lariae at ratios of 10:5:5:5:3:3:3:3:1.5:1.5 (Table  1). All 
air-dried herbs in AKQ are regionally well-known herbal 
medicines that are commercially used in China, and were 
purchased from Guangzhou Medicine Company (Guang-
zhou, China). The authenticity was identified by herb-
alists within that company, and re-confirmed by Prof. 
Ying-Jie Hu through morphological and anatomical iden-
tifications. The voucher specimens (AKQ HM-1–AKQ 
HM-10) were deposited at the Tropical Medicine Insti-
tute, Guangzhou University of Chinese Medicine.
The raw herbal materials were mixed and extracted in 
20 volumes of boiling water for 2 h, with the extraction 
repeated three times. The aqueous extracts were filtered 
and the suspension was collected. The filtrate was added 
to 2 volumes of 95 % (v/v) ethanol. The two suspensions 
were mixed thoroughly and left to stand for 10  h. The 
second mixture was filtered and the suspension was 
collected. The extraction solution was concentrated by 
stove-drying the residue, smashed to a fine powder, and 
stored in a desiccator until use.
Animals and study design
The nine juvenile male Ch-RMs (age: 3–6  years; body 
weight: 5.5–10.2 kg) used in this study were colony-bred 
rhesus macaques (Macaca mulatta) of Chinese origin 
that were maintained in accordance with the regula-
tions of the American Association for Assessment and 
Accreditation of Laboratory Animal Care at the Kunming 
Primate Research Center, Kunming Institute of Zoology, 
Chinese Academy of Sciences. All experimental proce-
dures were performed at the ABSL-3 Laboratory accord-
ing to the guidelines approved by the Ethics Committee 
of Kunming Institute of Zoology (Approval Number: 
SWYX-2011020; Additional file 1). Room temperature of 
the ABSL-3 Laboratory was maintained at 20–28 °C, with 
a relative humidity of 35–60 % and a 12-h/12-h light/dark 
cycle. The Ch-RMs were housed in stainless-steel cages 
(800 × 1000 × 1000 mm), and fed a monkey diet as well 
as fresh fruits, vegetables, and nuts. All animals had free 
access to feed and water ad  libitum. The general condi-
tions of the Ch-RMs, such as health status, behavior, 
eating habits, and stools, were observed daily by a veteri-
narian. The animal studies were performed following the 
ARRIVE guideline (Additional file 2).
All animals were demonstrated to be seronegative for 
SIVmac, simian T cell leukemia virus type 1, simian ret-
rovirus type 1 (type D retrovirus), and herpesvirus B. 
To allow for achievement of steady-state parameters, 
treatment was initiated at week 11 in the early phase 
of chronic infection and lasted for 8  weeks thereafter. 
Blood samples were obtained biweekly during the infec-
tion. One animal (#02067) in the control group died 
Table 1 Composition of Aikeqing
Chinese name English name Latin name Part used Composition ratio
Fuzi Radix AconitiLateralisPreparata Aconitum carmichaeli Debx. Black slice of root 10
Yinyanghuo Herba Epimedii Epimedium brevicornum Maxim. Overground portion 5
Ganjiang Rhizoma Zingiberis Zingiber officinaleRosc. Rhizoma 5
Gancao Radix Glycyrrhizae Glycyrrhiza uralensis Fisch. Root and Rhizoma 5
Renshen Radix Ginseng Panax ginseng C. A. Mey. Root 3
Danshen Radix SalviaeMiltiorrhizae Salvia miltiorrhizaBge. Root 3
Huzhang Rhizoma Polygoni Cuspidati Polygonum cuspidatum Sieb. etZucc. Root 3
Fuling Poria Poriacocos (Schw.) Wolf. Sclerotium 3
Huangbai Cortex Phellodendri Phellodendron chinensis Schneid. Bark 1.5
Huangqin Radix Scutellariae Scutellaria baicalensis Georgi Root 1.5
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at the initiation of therapy (day 5), suggesting that its 
immune response might not have been sufficient for 
protection against SHIV infection. All data from week 
12 onward refer to a total of two animals in the control 
group.
SHIV infection and treatment
The Ch-RMs were inoculated intravenously with 1000 
TCID50 (50  % tissue culture infectious doses) of cell-
free SHIV89.6 grown in CEM ×  174 cells. The animals 
were arbitrarily divided into three groups according to 
the cage placement within rooms in the animal house: 
control group (water 1 mL/kg): #02067, #06003, #06025; 
AKQ high-dose group (AKQ 1.65 g/kg): #03057, #04331, 
#06403; and AKQ low-dose group (AKQ 0.55  g/kg): 
#01089, #05077, #06311. AKQ was administered to the 
Ch-RMs once-daily by the intragastric route through a 
nasogastric tube (Sofine, Zhejiang, China).
Plasma collection
For blood collections, the animals were immobilized 
with ketamine-HCl (10  mg/kg body weight) injected 
intramuscularly at the lateral thigh muscles. Peripheral 
blood (5  mL) was collected into vacutainer tubes (Zhi-
yuan, Wuhan, China) containing EDTA-K2 as an antico-
agulant. Blood was collected from the lateral aspect of 
the hind limb. Plasma was separated by centrifugation of 
the blood in an Allegra X-12 centrifuge (Beckman Coul-
ter, Fullerton, CA, USA) at 900×g for 10 min at 4 °C, and 
stored at −80 °C until further processing and analysis.
Hematological parameter assays
Aliquots of blood (100 μL) were transferred to tubes for 
hematological analyses. Hematological parameters were 
measured using an automated hematological analyzer 
machine (BC-2800Vet; Mindray, Shenzhen, China). The 
abbreviations and units of the hematologic parameters 
are described in Table 2.
Lymphocyte phenotyping by flow cytometry
Peripheral blood lymphocyte subset analyses were per-
formed in a FACSCalibur flow cytometer (BD, Frank-
lin Lakes, NJ, USA) using a panel of mouse anti-human 
monoclonal antibodies known to cross-react with 
macaque receptors. Staining was performed on whole 
blood preparations. The lymphocyte subsets were stained 
for CD3 (PE; clone SP34; BD), CD4 (PerCP; clone L200; 
BD), and CD8 (FITC; clone RPA-T8; BD). The T cell sub-
set counts in the peripheral blood were determined by 
the TruCount™ method (BD, San Jose, CA, USA) using 
the FACSCalibur flow cytometer. The CD4+ and CD8+ 
T cell counts were reported as cell number/microliter.
Viral load measurement
Plasma samples were analyzed for viral RNA (vRNA) by 
real-time quantitative RT-PCR assays as described previ-
ously [8]. Briefly, vRNA was extracted with a High Pure Viral 
RNA Kit (Roche, Mannheim, Germany) in accordance with 
the manufacturer’s instructions. A two-step RT-qPCR assay 
using a PrimeScript™ RT Reagent Kit and Premix ExTaq™ 
(Takara, Dalian, China) was performed in a 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA, 
USA). Each sample was tested in triplicate. Viral loads were 
reported as vRNA copy numbers per milliliter of plasma. 
The detection limit of the assay was 100 vRNA copies/mL.
Statistical analysis
Statistical analyses were performed using SPSS software 
21.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 
version 6.0 (GraphPad Inc., San Diego, CA, USA). An 
independent-samples t-test was used for comparisons of 
differences in CD4+ T cell counts and plasma viral loads 
between two independent groups. A paired-samples t-test 
was used to compare CD4+ T  cell counts and plasma 
viral loads between different time points within the same 
group. Spearman’s correlation analysis was used to assess 
the relationships between CD4/CD8 ratio and CD4+ 
T  cell count, CD8+ T  cell count, or plasma vRNA level. 
Values of P < 0.05 were considered statistically significant.
Results
Side effects of AKQ during treatment
All animals had complete blood counts monitored in 
the early stage of treatment to identify any side effects 
of AKQ (Table 2). The appetite, stool, and conditions of 
the animals were observed daily by a veterinarian dur-
ing treatment. Most hematological parameters remained 
unchanged, and no obvious side effects were observed in 
the treated groups after 8 weeks of therapy. The high dose 
of AKQ (1.65 g/kg body weight) was tolerated in all ani-
mals without evidence of drug toxicity, the weights of the 
Ch-RMs remained relatively constant during AKQ treat-
ment, and no animals were euthanized.
AKQ treatment reduced plasma viral loads
Following intravenous infection (week 0), the plasma 
viral loads were measured biweekly throughout the study. 
As observed in our previous study [8], all animals became 
infected with variable peak and set point viral loads 
(Fig.  1). The majority of the animals maintained viral 
loads of 104–106 copies/mL for the duration of the exper-
iment. Higher levels of SHIV viremia might have resulted 
in significant pathogenesis and rapid disease progression 
in one animal in the control group (#02067), and this ani-
mal died at week 12 post-infection.
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Comparisons of animals from different groups revealed 
that treatment with high-dose AKQ induced a persistent 
decline (P  =  0.02) in plasma vRNA loads during treat-
ment (Fig.  1). The viral load copy numbers of the three 
Ch-RMs in the high-dose group decreased by 42–88  % 
(Fig. 1a), while no significant decrease (P = 0.06) in the 
plasma viral loads was detected in the low-dose group. 
Ch-RM #01089 (Fig.  1b, c) in the low-dose group also 
exhibited a sustained decline in viral load from the 
baseline value of 136,749–47,923  copies/mL at week 2 
post-treatment. The animals in the low-dose group and 
control group maintained persistent viremia compared 
with those in the high-dose group. The viral loads rapidly 
rebounded in the treated Ch-RMs following the cessation 
of treatment. In contrast to the variability of viral loads in 
the control group, the patterns of viral loads were similar 
in the high-dose group.
AKQ therapy transiently increased T cell counts
To estimate the effect of AKQ therapy on T lymphocytes, 
we measured the CD4+ and CD8+ absolute cell num-
bers. The CD4+ T cell counts showed slight increases or 
remained stable after AKQ administration in the high-
dose group compared with the baseline levels (P = 0.50; 
Fig. 2a) or the low-dose group (P = 0.53; Fig. 2b, c). The 
effect of AKQ treatment on the mean CD4+ T cell count 
was small and non-significant (P = 0.39) in the low-dose 
group. The increases in the peripheral T cell counts fol-
lowing AKQ treatment were transient and decreased 
rapidly after the end of treatment in the high-dose 
group.
Table 2 Hematological parameters of  SHIV89.6-infected 
Ch-RMs during Aikeqing treatment
Markers Group Weeks post administration of AKQ
0 2 4
WBC H 7.2 ± 2.0 8.1 ± 0.8 7.2 ± 1.1
L 7.0 ± 1.6 8.2 ± 0.4 8.4 ± 0.6
C 7.6 ± 1.9 8.0 ± 2.0 7.3 ± 2.3
Mon (%) H 7.3 ± 0.7 8.1 ± 2.2 7.7 ± 2.1
L 7.9 ± 0.9 8.9 ± 1.6 7.6 ± 0.9
C 7.6 ± 1.1 8.1 ± 1.3 8.2 ± 0.3
Mon (109/L) H 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.2
L 0.4 ± 0.2 0.4 ± 0.4 0.4 ± 0.2
C 0.6 ± 0.3 0.4 ± 0.3 0.7 ± 0.2
RDW (%) H 15.6 ± 0.3 16.4 ± 0.4 15.5 ± 0.1
L 15.8 ± 0.3 16.1 ± 0.3 15.5 ± 0.8
C 14.7 ± 0.6 16.2 ± 0.2 15.5 ± 1.0
RBC (1012/L) H 7.5 ± 0.4 6.6 ± 0.4 6.8 ± 0.1
L 7.1 ± 0.4 5.6 ± 0.4 6.0 ± 0.6
C 7.1 ± 0.3 6.0 ± 0.9 5.8 ± 0.8
HCT (%) H 58.7 ± 2.0 51.2 ± 3.4 53.9 ± 1.0
L 53.2 ± 2.9 42.8 ± 3.2 46.7 ± 4.9
C 52.9 ± 2.4 46.0 ± 7.2 45.6 ± 7.0
Lym (109/L) H 1.7 ± 0.3 2.0 ± 0.2 2.5 ± 0.5
L 1.5 ± 0.2 1.6 ± 0.6 2.0 ± 0.3
C 1.8 ± 0.5 1.8 ± 0.7 2.0 ± 0.3
Lym (%) H 22.4 ± 6.0 27.3 ± 10.5 36.9 ± 12.5
L 19.0 ± 9.7 17.4 ± 5.9 34.0 ± 7.8
C 22.8 ± 12.4 23.2 ± 22.0 32.7 ± 13.9
MCV (fL) H 74.6 ± 0.2 77.5 ± 0.5 79.0 ± 0.3
L 75.0 ± 0.5 76.9 ± 0.4 78.6 ± 0.2
C 74.3 ± 0.5 77.3 ± 0.8 78.5 ± 1.5
MCH (pg) H 24.4 ± 0.4 25.6 ± 0.6 26.8 ± 0.5
L 23.9 ± 1.2 25.0 ± 0.3 26.2 ± 0.2
C 22.9 ± 1.9 24.1 ± 1.9 24.2 ± 2.4
MCHC (g/L) H 328.3 ± 4.2 331.3 ± 7.8 339.3 ± 6.7
L 319.3 ± 13.9 326.0 ± 4.4 333.3 ± 3.2
C 309.0 ± 23.4 311.7 ± 22.0 308.3 ± 26.5
MPV (fL) H 7.2 ± 0.1 7.8 ± 0.6 8.0 ± 0.5
L 7.3 ± 0.1 7.9 ± 0.4 8.1 ± 0.3
C 6.9 ± 0.5 8.1 ± 0.5 7.6 ± 0.5
HGB (g/L) H 189.7 ± 5.0 176.3 ± 4.5 183.0 ± 1.0
L 170.0 ± 9.6 149.7 ± 8.1 156.0 ± 15.6
C 160.7 ± 14.2 158.0 ± 24.5 152.0 ± 24.8
PDW H 16.5 ± 0.1 16.6 ± 0.3 16.6 ± 0.2
L 16.8 ± 0.5 16.3 ± 0.2 16.3 ± 0.2
C 16.6 ± 0.1 16.3 ± 0.2 16.2 ± 0.2
PLT (109/L) H 410.0 ± 76.3 367.0 ± 60.9 287.7 ± 27.1
L 331.7 ± 27.7 440.3 ± 67.3 372.7 ± 61.2
C 418.0 ± 25.0 459.7 ± 24.0 377.7 ± 51.9
Table 2 continued
Markers Group Weeks post administration of AKQ
0 2 4
PCT (%) H 0.3 ± 0.1 0.3 ± 0.0 0.2 ± 0.0
L 0.2 ± 0.1 0.4 ± 0.1 0.3 ± 0.1
C 0.2 ± 0.1 0.4 ± 0.0 0.3 ± 0.1
Gran (109/L) H 3.8 ± 0.7 5.6 ± 4.6 2.9 ± 1.4
L 2.9 ± 0.2 4.4 ± 2.0 2.2 ± 1.3
C 2.4 ± 0.8 4.6 ± 1.5 2.7 ± 0.7
Gran (%) H 71.3 ± 7.1 63.9 ± 6.6 58.1 ± 12.6
L 72.8 ± 8.2 71.0 ± 7.7 60.0 ± 7.5
C 70.3 ± 14.0 69.6 ± 12.5 64.5 ± 8.4
H high-dose group, L low-dose group, C control group, WBC white blood cells, 
Mon monocytes, RDW red blood cell volume distribution width, RBC red blood 
cells, HCT haematocrit, Lym lymphocytes, MCV mean corpuscular volume, 
MCH mean corpuscular haemoglobin, MCHC mean corpusular hemoglobin 
concerntration, MPV mean platelet volume, HGB haemoglobin, PDW platelet 
distribution width, PLT platelets, PCT plateletcrit, Gran granulocytes
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The CD8+ T  cell counts were slightly increased after 
treatment in the high-dose group (Fig. 3a). No significant 
change (P = 0.57) was observed in the high-dose group 
compared with the low-dose group (Fig. 3b, c).
Effect of AKQ treatment on the CD4/CD8 ratio
All animals had a persistently high CD4/CD8 ratio (>1) 
after SHIV89.6 infection, and no significant difference 
(P  =  0.24) was found between the high-dose group 
and the low-dose group (Fig.  4). Interestingly, further 
analysis indicated that the CD4/CD8 ratio in the con-
trol group showed negative correlations with the viral 
load and CD8+ T cell count (rho = −0.58, P = 0.03 and 
rho = −0.94, P < 0.0001, respectively), but not with the 
CD4+ T cell count (rho = −0.17, P = 0.55). The findings 
of the present study were consistent with those in a previ-
ous study by Serrano-Villar et al. [9]. However, the results 
for the high-dose group were quite different. In the high-
dose group, a positive correlation was found between the 
CD4/CD8 ratio and the CD4+ T cell count (rho = 0.72, 
P  <  0.01), and no significant correlations were found 
between the CD4/CD8 ratio and the CD8+ T cell count 
or viral load (Fig. 5). These results suggest that treatment 
with AKQ resulted in an increase in CD4+ T lympho-
cytes. The high CD4+ T cell count and consequently the 
high CD4/CD8 ratio might suggest successful recovery of 
CD4+ T cells. 
Discussion
The present study analyzed the effects of AKQ admin-
istration on viral loads, CD4+ T  cell counts, and CD8+ 
T  cell counts in SHIV89.6-infected Ch-RMs. To our 
knowledge, this is the first attempt to study the effect 
of a Chinese medicine in SHIV89.6-infected Ch-RMs. 
Fig. 1 AKQ reduces plasma viral loads in chronically SHIV89.6‑infected Ch‑RMs. Nine SHIV89.6‑infected Ch‑RMs were randomly divided into three 
groups (n = 3 per group), and treated with 1.65 g/kg/day AKQ (a), 0.55 g/kg/day AKQ (b), or placebo (c) for 8 weeks. The gray-shaded areas indicate 
the treatment period. The dotted lines indicate the results obtained from individual animals, and the solid lines represent the mean values for the 
groups. Plasma viral loads were measured by real‑time PCR assays with a sensitivity of 100 vRNA copies/mL
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Weeks post SHIV89.6 infection
Fig. 2 Changes in CD4+ T cell counts in peripheral blood. The absolute CD4+ T cell counts remained stable or increased after treatment in the 
high‑dose group (a), compared with those in the low‑dose group (b) or control group (c). No significant changes were observed for the CD4+ T cell 
counts in the treated and untreated groups before and after treatment
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Ch-RMs develop AIDS-like symptoms more slowly than 
Indian macaques when exposed to SIV or SHIV [10]. 
Mothé et al. [11] reported Ch-RM MHC immunogenetics 
are more similar to HLA than those of Indian macaques, 
and therefore that Ch-RMs might be a better model for 
HIV. The SIV-infected Ch-RM has been successfully used 
as a model for studying responses to combination antiret-
roviral therapy (ART) and evaluating candidate eradica-
tion strategies to cure HIV infection [12]. Our study was 
performed to develop a chronically SHIV89.6-infected 
Ch-RM model for detailed investigation of Chinese 
medicine therapeutic effects. High-dose AKQ therapy 
reduced the viral loads in SHIV89.6-infected Ch-RMs 
when initiated early after infection, thereby preventing 
the immunologic damage caused by HIV-1. AKQ treat-
ment showed a beneficial effect on T cell recovery in the 
SHIV89.6-infected animals in accordance with previous 
findings in a clinical study [5].
In untreated HIV-infected patients, the CD4/CD8 
ratio can be used not only as a predictor of poor prog-
nosis [13], but also as a predictor of immune restoration 
[14] and AIDS-related morbidities. Serrano-Villar et  al. 
[9] reported that patients with early initiation of ART 
were more likely to achieve a higher CD4/CD8 ratio 
than patients with later initiation of ART (2  years after 
infection). To our knowledge, no studies have specifically 
addressed the clinical significance of the CD4/CD8 ratio 
in SHIV-infected Ch-RMs on therapy. In our study, the 
animals in the high-dose group displayed a CD4/CD8 
ratio increase from their baseline level before AKQ initia-
tion. Meanwhile, a significant increase in the CD4/CD8 
ratio failed to appear because the increase in CD4+ T cells 
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Weeks post SHIV89.6 infection
Fig. 3 Changes in CD8+ T cell counts in peripheral blood. The CD8+ T cell counts were assessed in the high‑dose group (a), low‑dose group (b), 
and control group (c). No significant changes were observed for the CD8+ T cell counts in the treated and untreated groups before and after treat‑
ment
Fig. 4 Effect of treatment on peripheral blood CD4/CD8 T cell ratios. The CD4/CD8 T cell ratio remained at a consistently high level in the high‑dose 
group (a), low‑dose group (b), and control group (c) during the treatment. No significant changes were observed in the treated and untreated 
groups before and after treatment
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was accompanied by a simultaneous increase in CD8+ 
T cells. In the untreated animals, the CD4/CD8 ratio 
showed strong correlations with the CD8+ T  cell count 
and plasma vRNA level, but not with the CD4+ T  cell 
count. Remarkably, the associated relationships changed 
and only the CD4+ T  cell count was positively corre-
lated with the CD4/CD8 ratio in the high-dose group 
after treatment. We assumed that the CD4/CD8 ratio 
was essentially dependent on the CD4+ T  cell count in 
the animals with successful CD4+ T cell recovery. Helle-
berg et al. [15] reported that a major decline in the CD4+ 
T cell count was associated with markedly increased risks 
of cardiovascular disease, cancer, and death among ART-
treated HIV patients. Takuva et  al. [16] reported that 
patients on ART with poor CD4+ T cell recovery during 
early treatment were at greater risk of progression to new 
AIDS diagnosis or death despite viral suppression.
Baicalein and baicalin, isolated from Scutellaria bai-
calensis Georgi, were shown to be potent inhibitors of 
integrase and reverse transcriptase from HIV-1 [17]. 
Liu et  al. [18] reported that crude extracts from Cortex 
Phellodendri exhibited antifungal activities in  vitro, and 
suggested their use for treatment of candidiasis in HIV/
AIDS patients. Tang et  al. [19] reported that a crude 
extract of Rhizoma Polygoni Cuspidati inhibited HIV-1 
reverse transcriptase. Abd-Elazem et  al. [20] reported 
that water-soluble extracts of Salvia miltiorrhiza Bge. 
inhibited HIV-1 integrase activities. All of these findings 
suggest that AKQ may suppress viral replication at multi-
ple steps in the life cycle of HIV-1.
Many people living with HIV/AIDS in China are using 
complementary medicine [21]. In 1996, a randomized 
trial tested a Chinese herbal formulation composed of 
31 Chinese herbs in 30 HIV patients for treatment of 
HIV-related symptoms for a duration of 12  weeks. The 
study found that the symptoms were reduced in patients 
receiving the herbal formulation, but not in those receiv-
ing the placebo [22]. However, no significant differences 
were found between the two groups in a follow-up study 
[23]. A recent study showed that indirubin, the active 
ingredient of the Chinese herbal formula Dan Gui Long 
Hui Wan, suppressed viremia of multidrug-resistant 
HIV molecular clones in animal models [24]. HAART 





























































































































Fig. 5 Correlations of the CD4/CD8 ratio with the CD4+ T cell count, CD8+ T cell count, or plasma viral load in the treated or untreated Ch‑RMs. 
Spearman’s correlations were analyzed in the control group (top panel) and high‑dose group (bottom panel). The CD4/CD8 ratio was negatively 
correlated with the plasma viral load in the control group (a), but no correlation was found in the high‑dose group (b). The CD4/CD8 ratio was posi‑
tively correlated with the CD4+ T cell count in the high‑dose group (d), but no correlation was found in the control group (c). The CD4/CD8 ratio 
was negatively correlated with the CD8+ T cell count in the control group (e), but no correlation was observed in the high‑dose group (f)
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eliminate the latent viral reservoir. The goal of HIV ther-
apy is immune control of virus replication, rather than 
eradication. A combination of anti-inflammatory, antiret-
roviral, and immunological therapies might lead to total 
viral suppression and restoration of immune function in 
AIDS patients [25, 26]. AKQ at an appropriate concen-
tration (1.65  g/kg) decreased the plasma viral loads in 
SHIV89.6 chronically-infected Ch-RMs. AKQ was effec-
tive in preventing the decline of circulating CD4+ T cells. 
The largest increase in CD4+ T cells after treatment was 
observed in the high-dose group, which corresponded 
well with the significant decrease in the SHIV89.6 viral 
loads in this group.
One possible limitation of the present study was the small 
number of animals analyzed in each group. In accordance 
with the 3R (replacement, reduction, and refinement) prin-
ciples [27], we used three Ch-RMs per group in an 8-week 
test for AKQ treatment. To minimize the experimental var-
iables, we carefully controlled some animal characteristics, 
such as age and weight, in our study.
Conclusion
AKQ reduced plasma viral loads in the SHIV89.6-
infected Chinese rhesus macaque model.
Abbreviations
ART: antiretroviral therapy; HAART: highly active antiretroviral therapy; AKQ: 
Aikeqing; Ch‑RMs: Chinese‑origin rhesus macaques; HIV: human immuno‑
deficiency virus; SIV: simian immunodeficiency virus; SHIV: simian‑human 
immunodeficiency virus.
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